The therapeutic potency of Th17 cells over Th1 or Th2 cells has been reported by many 51 groups using mouse model systems (2-5). Surprisingly, the impact of tumor-specific human 52 + ) when redirected with a chimeric 56 antigen receptor (CAR) and infused into hosts bearing human tumors (6). Moreover, the 57 therapeutic potential of naturally arising human CD4 subsets-sorted from the peripheral blood 58 via classic surface markers-engineered with a CAR has yet to be elucidated. 59 We 
CD26 high T cells lyse tumor target cells in vitro 144
Given the pronounced capacity of CD26 high T cells to co-secrete multiple cytokines, we tested if 145 they would be more effective at lysing human tumors than Th1, Th2 or Th17 cells in vitro. To 146 address this, we engineered these helper populations to express chimeric antigen receptor that 147 recognizes mesothelin (meso-CAR) and co-cultured them with mesothelin-positive K562 tumor 148 cells ( Figure S2A ). As anticipated, CD26 high T cells lysed tumor targets at a lower effector to 149 target (E:T) ratio compared to all other subsets when co-cultured overnight ( Figure S2B ). In this 150 assay, Th1, Th17 and bulk CD4 + T cells similarly lysed targets at equal E:T ratios, whereas a 151 greater number of Th2 cells were needed to lyse targets. 
CD26
high T cells demonstrate enhanced tumor immunity compared to other helper subsets 157
Next, we set out to test the relative antitumor activity of these CD4 + T helper populations in vivo. 158
As in Figure S2A , we engineered sorted Th1, Th2, Th17, CD26 high , and bulk CD4 + T cells to 159 express mesothelioma specific-CAR and infused them into NSG mice bearing a large established 160 tumor. Note that we used a 1 st generation meso-CAR, reported by our colleagues to be less 161 therapeutic than 2 nd generation meso-CARs (9), as we surmised this approach would generate a 162 treatment window to address whether CD26 high T cells lyse tumor to a greater extent than other 163 subsets. 
Study Design 253
Sample Size: As these experiments were exploratory, there was no estimation to base the 254 effective sample size; therefore, we based our animal studies using sample sizes ≥ 5.
Rules for 255
Stopping Data Collection: experimental endpoints were designated prior to study execution. 256
Tumor control studies were conducted over ~70 days. Data Inclusion/exclusion: for experiments 257 reported herein, animals were only excluded if tumors were very small or not measurable, a rule 258 established prospectively prior to any therapy initiation. Outliers: Outliers were reported. 259
Endpoints: Tumor endpoint was reached when tumor area exceeded 400mm 2 . Remaining mice 260 were euthanized and spleens were harvested when more than half of the mice in a group reached 261 tumor endpoint. Randomization: Prior to therapy, mice were randomized based on tumor size. 262
Blinding: Tumors were measured using L x W measurements via calipers by personnel blinded 263 to treatment group. 264
265

Statistical Analysis 266
Tumor area results were transformed using the natural logarithm for data analysis. Mixed effects 267 linear regression models with a random component to account for the correlation of the repeated 268 measure within a mouse were used to estimate tumor area over time. In circumstances where 269 linearity assumptions were not met, polynomial regression models were used (27). Linear 270 combinations of the resulting model coefficients were used to construct estimates for the slope 271 differences with 95% confidence intervals where applicable. For polynomial models, estimates 272 were constructed for the differences in area between groups on the last day where at least one 273 mouse was alive in all groups. Experiments with multiple groups were analyzed using one-way 274 analysis of variance (ANOVA) with post comparison of all pair wise groups using Tukey's range 275 test. Experiments comparing two groups were analyzed using a Student's t test. The center 276 values are the mean and error bars are calculated as the SEM. TCRβ sequencing analysis was 277 based on the log-linear model and the 'relative risks' calculated with a 95% confidence interval. Sorted T cells were centrifuged and washed in PBS, and genomic DNA was extracted using 333
Wizard Genomic DNA purification kit (Promega). The quantity and purity of genomic DNA was 334 assessed through spectrophotometric analysis using NanoDrop (ThermoScientific). 335
Amplification of TCR genes was done within the lab using the ImmunoSEQ hsTCRβ kit 336 
CD26
high or bulk CD4 + cells were sorted from normal donor PBL and expanded with 569 αCD3/ICOS bead at a 1 bead:10 T cell ratio. Cells were transduced with a 1 st generation 570 mesothelin-specific CD3ζ CAR and expanded with IL-2. NSG mice bearing mesothelioma were 571 treated with 4×10 6 transduced, sorted CD4 + cells + 4×10 6 transduced CD8 + cells and 50,000 IU 572 IL-2 was given to each mouse daily for 3 days. B) Single tumor curves overlaid with average 573 curve (red) and C) average tumor curves of 6-9 mice/group. All groups were significantly 574 different from NT, P < 0.005. CD4 vs. Th1 NS; CD4 vs. Th2, P = 0.0015 (**); CD4 vs. Th17, P 575 = 0.0035 (**); CD4 vs. CD26 
